Table 2.
Selected examples of investigations where the anti-tumor agent was protected by an NP during transport through the body and where the antineoplastic effect was expressed prolonged survival
| Nanoparticle | Targeting ligand | Therapeutic agent | Tumor | Animal | Ref. |
|---|---|---|---|---|---|
| Polymer | Biotin | Paclitaxel + tariquidar | “transformed murine” | Mice | [153] |
| Polymer | None | Dox/curcumin | Four human malignancies | Mice | [265] |
| Liposome | Peptide | Dox | Human neuroblastoma | Mice | [266] |
| Chitosan-NP | mirRNA | Paclitaxel | Human ovarian cancer | Mice | [267] |
| Polymer | Local injector | Dithiazanin | MGB | Rats | [268] |
| Polymer | Abs, vs ABC G2 | Paclitaxel + siRNA | Human breast cancer | Mice | |
| Polymer | None stated | Dox + Mitomyzin | Human breast cancer | Mice | [269] |
| Polymer | Photodynamic and chemotherapy | Dox | Human breast cancer | Mice | [270] |
GR growth reduction, PS prolonged survival, Wt wild type